Roivant Sciences Nears $7B+ Deal with Roche for TL1A Antibody RVT-3101

On July 13, according to a report by The Wall Street Journal, Roivant Sciences may sell its ulcerative colitis candidate drug RVT-3101 to Roche, in a deal potentially worth over $7 billion.

Pfizer announced in December last year that it had established a new company named Vant with Roivant Sciences, focusing on the development and commercialization of RVT-3101. According to the agreement, Vant holds the commercial rights of RVT-3101 in the United States and Japan. Pfizer owns 25% of Vant's equity, enjoys its commercial rights outside the United States and Japan, and has representation on the company's board of directors. According to The Wall Street Journal, it is currently unclear what impact the sale of the drug to Roche will have on Pfizer's interests.

RVT-3101 is a potential first-in-class drug that exerts its therapeutic effects by inhibiting tumor necrosis factor-like ligand 1A (TL1A) to block inflammation and fibrosis pathways.

RVT-3101 is currently in Phase III trials for the treatment of ulcerative colitis. The company announced the 56-week data from the Phase IIb TUSCANY-2 study of the drug in June. At the anticipated Phase III dose, with patients receiving subcutaneous injections of RVT-3101 once a month, the proportion of patients achieving clinical remission (36% at week 56, 29% at week 14) and endoscopic improvement (50% at week 56, 36% at week 14) increased.

According to Roivant's website, the drug is also being developed for the treatment of Crohn's disease and is currently in Phase II trials.

Roivant, headquartered in the UK, has at least 13 subsidiaries focused on drug development. The company was founded by Vivek Ramaswamy, who is currently seeking the Republican presidential nomination. Ramaswamy served as Roivant's chairman until stepping down at the end of February to focus on his own career.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message to the WeChat Official Account's backend or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Online Live Streaming & Offline Salon